Former Pershing Square analyst Shane Dinneen is probably best known as the co-author of Pershing’s Herbalife Ltd. (NYSE:HLF) short, before resigning earlier this year. There had been speculation that the pressure of having led the research leading to such a high-profile and controversial short, but that doesn’t seem to be true now that he has reopened his case in a recent article on Seeking Alpha.
“Herbalife's headline numbers in Q1 seem good at first blush, but below the surface, cracks are beginning to appear in the foundation,” writes Shane Dinneen, who bypasses...
Login required to continue reading.
Setup a free account to get access to this article (no credit card required).
View Full ArticleAlready a member? Log in here
